By Mill Chart
Last update: Jan 24, 2024
SANOFI-ADR (NASDAQ:SNY) was identified as a stock worth exploring by dividend investors by our stock screener. NASDAQ:SNY scores well on profitability, solvency and liquidity. At the same time it seems to pay a decent dividend. We'll explore this a bit deeper below.
To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NASDAQ:SNY has achieved a 7 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:SNY has achieved a 7 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:SNY has earned a 8 out of 10:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
Check the latest full fundamental report of SNY for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
SANOFI-ADR
NASDAQ:SNY (4/26/2024, 7:16:56 PM)
After market: 49.13 0 (0%)49.13
-0.23 (-0.47%)
/PRNewswire/ -- SobiĀ® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion...
SNY earnings call for the period ending March 31, 2024.
SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.